Cytokine Expression in Multiple Myeloma and Monoclonal Gammopathy: Analysis by Reverse Transcription/Polymerase Chain Reaction and Quantitative PCR
- 1 January 1996
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 24 (1-2) , 111-120
- https://doi.org/10.3109/10428199609045719
Abstract
Cytokine messenger RNA expression was studied using the reverse transcription/polymerase chain reaction in 23 patients with multiple myeloma (MM), 16 with monoclonal gammopathy of undetermined significance (MGUS), 12 with post menopausal osteoporosis (OP) and 12 normal controls. Messenger RNAs for IL-1α, IL-1β, TNF-α, TNF-β, IL-6 and M-CSF were sought in view of their reported pathogenic role in myeloma. Transcripts for IL-1β, TNF-α, TNF-β and M-CSF were found frequently in all four groups of patients. The only significant difference in cytokine expression between the groups was for IL-6 which was expressed in 17% of controls compared with 87% of patients with MM (p < 0.001), 62% of patients with MGUS (p < 0.02) and 67% of patients with osteoporosis (p < 0.02). Further analysis of IL-6 expression by quantitative PCR showed significantly higher IL-6 mRNA levels in MM compared with MGUS (p < 0.006). There was no correlation however between expression of individual cytokines and clinical features of myeloma such as osteolytic bone disease or hypercalcaemia. We conclude that expression of IL-6 mRNA is significantly enhanced in multiple myeloma when compared with MGUS. However, since MGUS and osteoporosis were also associated with a high prevalence of IL-6 expression when compared with controls it is probable that factors other than IL-6 are responsible for the local osteolytic lesions which characterise MM, but which are not seen in MGUS or osteoporosis.Keywords
This publication has 36 references indexed in Scilit:
- Why better prognostic factors for multiple myeloma are needed [editorial] [see comments]Blood, 1994
- Interleukin-6 in Multiple Myeloma: Correlation with Disease Activity and Ki-67 Proliferation IndexLeukemia & Lymphoma, 1994
- Adhesion to high endothelial venules: a model for dissemination mechanisms in non-Hodgkin's lymphomaBlood, 1993
- Radioimmunoassay for the measurement of serum IL‐6 and its correlation with tumour cell mass parameters in multiple myelomaAmerican Journal of Hematology, 1992
- Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.Journal of Clinical Investigation, 1991
- Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]Blood, 1991
- Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parametersAnnals of Hematology, 1991
- The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with MyelomaLeukemia & Lymphoma, 1991
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).Proceedings of the National Academy of Sciences, 1985